Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.46 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29735324 | 1.00 | PLAU (0.54) | PLAUMKNK1MKNK2IKBKBEGFR | |
| Hydrochloric Acid SCHEMBL9792812 | 0.88 | MKNK1 (0.52) | MKNK1MKNK2CHUKALDH1A1KMO | |
| SCHEMBL29516759 | 0.86 | CHUK (0.56) | MKNK1MKNK2IKBKBCHUKIKBKE | |
| SCHEMBL725162 | 0.84 | KMO (0.62) | PLAUEGFRALDH1A1KMOHDAC1 | |
| SCHEMBL27882253 | 0.84 | EGFR (0.50) | PLAUEGFRALDH1A1KMOHDAC1 | |
| SCHEMBL7229397 | 0.84 | MKNK1 (0.58) | PLAUMKNK1MKNK2DHODHALDH1A1 | |
| SCHEMBL7064288 | 0.83 | MKNK1 (0.57) | MKNK1MKNK2IKBKBCHUKALDH1A1 | |
| Biphenyl SCHEMBL27646748 | 0.82 | LMNA (0.61) | ALDH1A1HDAC1 | |
| SCHEMBL933914 | 0.82 | MKNK1 (0.59) | MKNK1MKNK2ALDH1A1KMOCOMT | |
| SCHEMBL30761107 | 0.82 | MKNK1 (0.59) | MKNK1MKNK2ALDH1A1KMOCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1846424-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2024-04-18 | — | — | US | disclosed |
| EP-4263520-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2023-10-25 | — | — | EP | disclosed |
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022133529-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022133529-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-0189678-B1 | ELECTROCHEMICAL REDUCTIONS OF PYRIDINE CARBOXAMIDE BASES | REILLY INDUSTRIES, INC. (US) | 1991-11-06 | — | — | EP | disclosed |
| US-4695352-A | Electrochemical reduction of pyridine carboxamide bases | REILLY TAR & CHEMICAL CORPORATION (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0189678-A1 | Electrochemical reductions of pyridine carboxamide bases | REILLY INDUSTRIES, INC. (US) | 1986-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | PLAU 150/4885MKNK1 2187/4885MKNK2 2493/4885 |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | TYRO3, RET, AXL | PLAU 1724/4885MKNK1 744/4885MKNK2 990/4885 |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PLAU 3144/4885MKNK1 692/4885MKNK2 915/4885 |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PLAU 3144/4885MKNK1 692/4885MKNK2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.